Increased A3AR-dependent vasoconstriction in diabetic mice is promoted by myeloperoxidase

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 5, 2014, Pages 465-472

  Nishat, Shamama ^a,b   Klinke, Anna ^b,c   Baldus, Stephan ^b,c   Khan, Luqman Ahmad ^a   Basir, Seemi Farhat ^a  

^a JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Adenosine A3 receptor; Diabetes; Myeloperoxidase; Reactive oxygen species; Vasoconstriction

Indexed keywords

ADENOSINE A3 RECEPTOR; MYELOPEROXIDASE; STREPTOZOCIN; 2-CHLORO-N(6)-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLURONAMIDE; ADENOSINE; ADENOSINE A3 RECEPTOR AGONIST; PEROXIDASE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DIABETIC ANGIOPATHY; ENZYME BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; ISOMETRICS; MALE; MOLECULAR PATHOLOGY; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASOCONSTRICTION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADENOSINE; ADENOSINE A3 RECEPTOR AGONISTS; ANIMALS; AORTA; DIABETES MELLITUS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEROXIDASE; RECEPTOR, ADENOSINE A3; STREPTOZOCIN; SUPEROXIDES; VASOCONSTRICTION;

EID: 84927712575     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000139     Document Type: Article

References (50)

1. Haskó G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25:33-39.
2. Tabrizchi R, Bedi S. Pharmacology of adenosine receptors in the vasculature. Pharmacol Ther. 2001;91:133-147.
3. Fredholm BB, IJzerman AP, Jacobson KA, et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527-552.
4. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247-264.
5. Headrick JP, Peart J. A3 adenosine receptor-mediated protection of the ischemic heart. Vascul Pharmacol. 2005;42:271-279.
6. Black RG Jr, Guo Y, Ge ZD, et al. Gene dosage-dependent effects of cardiac-specific over expression of the A3 adenosine receptor. Circ Res. 2002;91:165-172.
7. Guo Y, Bolli R, Bao W, et al. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol. 2001;33:825-830.
8. Zhao Z, Francis CE, Ravid K. An A3-subtype adenosine receptor is highly expressed in rat vascular smooth muscle cells: its role in attenuating adenosine-induced increase in cAMP. Microvasc Res. 1997;54: 243-252.
9. Zhao Z, Makaritsis K, Francis CE, et al. A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim Biophys Acta. 2000;1500:280-290.
10. Talukder MA, Morrison RR, Jacobson MA, et al. Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. Am J Physiol Heart Circ Physiol. 2002;282: H2183-H2189.
11. Headrick JP, Peart JN, Wan TC, et al. Cardiovascular biology of the A3 adenosine receptor. In: Borea PA, ed. A3 Adenosine Receptors From Cell Biology to Pharmacology and Therapeutics. Dordrecht: Springer; 2010:192.
12. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77: 598-625.
13. Asselbergs FW, Reynolds WF, Cohen-Tervaert JW, et al. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med. 2004;116:429-430.
14. Nikpoor B, Turecki G, Fournier C, et al. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001;142:336-339.
15. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels asnd risk of coronary artery disease. J Am Med Assoc. 2001; 286:2136-2142.
16. Sugiyama S, Kugiyama K, Aikawa M, et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression. Involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis, Arterioscler Thromb Vasc Biol. 2004;24: 1309-1314.
17. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al. A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int Suppl. 2003;84:S172-S176.
18. Askari AT, Brennan ML, Zhou X, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615-624.
19. Baldus S, Heeschen C, Meinertz T, et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440-1445.
20. Sugiyama S, Okada Y, Sukhova GK, et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879-891.
21. Baldus S, Eiserich JP, Mani A, et al. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J Clin Invest. 2001;108:1759-1770.
22. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocytederived vascular NO oxidase. Science. 2002;296:2391-2394.
23. Rudolph V, Rudolph TK, Hennings JC, et al. Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function. Free Radic Biol Med. 2007;43:1189-1196.
24. Rudolph TK, Wipper S, Reiter B, et al. Myeloperoxidase deficiency preserves vasomotor function in humans. Eur Heart J. 2012;33: 1625-1634.
25. Stehouwer CD, Lambert J, Donker AJ, et al. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34:55-68.
26. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia. 2000;43: 1205-1223.
27. Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol. 2004; 44:397-405.
28. Duby JJ, Campbell RK, Setter SM, et al. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004;61:160-173.
29. Goldberg RB. Cardiovascular disease in patients who have diabetes. Cardiol Clin. 2003;21:399-413.
30. Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy. Am J Kidney Dis. 2003;41(3 suppl 1):S19-S21.
31. Porta M, Bandello F. Diabetic retinopathy: a clinical update. Diabetologia. 2002;45:1617-1634.
32. De-Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Clin Nutr Metab Care. 2000;3:453-467.
33. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: The role of endothelial dysfunction. Clin Sci (Lond). 2005; 109:143-159.
34. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res. 2007;125:451-472.
35. Revsin Y, van-Wijk D, Saravia FE, et al. Adrenal hypersensitivity precedes chronic hypercorticism in streptozotocin-induced diabetes mice. Endocrinology. 2008;149:3531-3539.
36. Pomerleau F, Fournier A, Cadieux A. Mouse aorta: a preparation highly sensitive to the vasodilatory action of CGRP. J Cardiovasc Pharmacol. 1997;30:343-351.
37. Ansari HR, Nadeem A, Tilley SL, et al. Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta. Am J Physiol Heart Circ Physiol. 2007;293:H3448-H3455.
38. Grden M, Podgórska M, Szutowicz A, et al. Altered expression of adenosine receptors in heart of diabetic rat. J Physiol Pharmacol. 2005;56: 587-597.
39. Nussbaum C, Klinke A, Adam M, et al. Myeloperoxidase: a leukocyte derived protagonist inflammation and cardiovascular disease. Antioxid Redox Signal. 2013;18:692-713.
40. El-Awady MS, Ansari HR, Fil D, et al. NADPH oxidase pathway is involved in aortic contraction induced by A3 adenosine receptor in mice. J Pharmacol Exp Ther. 2011;338:711-717.
41. Heilman K, Zilmer M, Zilmer K, et al. Arterial stiffness, carotid artery intima-media thickness and plasma myeloperoxidase level in children with type 1 diabetes. Diabetes Res Clin Pract. 2009;84:168-173.
42. Kataoka Y, Shao M, Wolski K, et al. Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: Insightsfrom Intravascular ultrasound. Atherosclerosis. 2014; 232:377-383.
43. Nesto RW, Rutter MK. Impact of the atherosclerotic process in patients with diabetes. Acta Diabetol. 2002;39(suppl 12):S22-S28.
44. Aragno M, Tamagno E, Gatto V, et al. Dehydro epiandrosterone protects tissues of streptozotocin-treated rats against oxidative stress. Free Radic Biol Med. 1999;26:1467-1474.
45. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, et al. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab. 2000;26:163-176.
46. Mohamed AK, Bierhaus A, Schiekofer S, et al. The role of oxidative stress, NF-Kappa b activation in late diabetic complications. Biofactors. 1999;10:157-167.
47. Drummond GR, Selemidis S, Griendling KK, et al. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011;10:453-471.
48. El-Awady MS, Rajamani U, Teng B, et al. Evidence for the involvement of NADPH oxidase in adenosine receptors-mediated control of coronary flow using A1 and A3 knockout mice. Physiol Rep. 2013;1:e00070.
49. 2+/ROS-dependent down regulation of ERK and Akt in A172 human glioma cells. Neurochem Res. 2012;37: 2667-2677.
50. Lau D, Szöcs K, Klinke A, et al. Myeloperoxidase upregulates endothelin receptor type B expression. J Mol Cell Cardiol. 2014;69:76-82.